Megabios, Pfizer deal

The companies will collaborate to develop gene therapy products to treat solid tumors intravenously by inhibiting angiogenesis. The initial target is non-small cell lung cancer. Pfizer receives worldwide rights in exchange for up to $50 million in funding, which includes equity investments, research funding for up to four years and milestones. Megabios will receive royalties. ...